• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MET Gene Record

  • Summary
  • Interactions
  • Claims
  • MET 4233 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    4233
    MET PROTO-ONCOGENE, RECEPTOR TYROSINE KINASE
    MET
    AUTS9
    DFNB97
    HGFR
    RCCP2
    c-Met
    164860
    7029
    ENSG00000105976
    OTTHUMG00000023299
    MET_HUMAN
    P08581
    HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581]
    HEPATOCYTE GROWTH FACTOR RECEPTOR
    1815
    BE0000915
    PA30763
    SF receptor
    HGF receptor
    Tyrosine-protein kinase Met
    Scatter factor receptor
    Proto-oncogene c-Met
    HGF/SF receptor
    52
    NP_000236
    NM_000245
    T40474

    Gene Info:

    Initial Gene Query MET
    Counted Citations from 1950-2000 4560
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name KINASE
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level
    Uniprot Status Swiss-Prot
    Interpro Acc IPR001245
    Interpro Short Name Ser-Thr/Tyr_kinase_cat_dom
    Interpro Name Serine-threonine/tyrosine-protein kinase catalytic domain
    CancerCommons Reported Gene Name MET
    CancerCommons Reported Gene Name MET, VEGFRs, Axl, Tie2, Ron
    GuideToPharmacology Gene Category Name Type X RTKs: HGF (hepatocyte growth factor) receptor family
    GuideToPharmacology Gene Category ID 325
    Target Class Receptors
    Target Subclass EC:2.7.10.1
    Gene Biotype PROTEIN_CODING
    (31 More Sources)

    Gene Categories: Category Details

    CELL SURFACE
    KINASE
    TYROSINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE

    Publications:

    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Patnaik et al., 2014, Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma., Br. J. Cancer
    Phillip et al., 2013, Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines., J Hematol Oncol
    Awad et al., 2016, MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression., J. Clin. Oncol.
    Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.
    Secrier et al., 2016, Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance., Nat. Genet.
    Heist et al., 2016, Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping., J Thorac Oncol
    Tanizaki et al., 2011, MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations., J Thorac Oncol
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.
    Forde et al., 2012, Crizotinib in the treatment of non-small-cell lung cancer., Expert Opin Pharmacother
    Moro-Sibilot D et al., 2019, Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial., Ann Oncol
    Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
    Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
    Le et al., 2015, Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling., Clin Lung Cancer
    Chi et al., 2012, Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor., J. Clin. Oncol.
    Landi L et al., 2019, Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial., Clin Cancer Res
    Wiesweg M et al., 2020, Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation., Lung Cancer
    Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med
    Paik et al., 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping., Cancer Discov
    Ou et al., 2011, Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification., J Thorac Oncol
    Zou et al., 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms., Cancer Res.
    Pietrantonio et al., 2016, MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer., Cancer Discov
    Pfefferle et al., 2016, Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers., Dis Model Mech
    Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther
    Drilon A et al., 2020, Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration., Nat Med
    Shen et al., 2015, c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers., Cancer Res.
    Palma et al., 2014, Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary., Case Rep Oncol
    Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.
    Qi et al., 2011, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors., Cancer Res.
    Mahjoubi L et al., 2016, A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib., Invest New Drugs
    Ou et al., 2016, High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression., Lung Cancer
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Chabon et al., 2016, Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients., Nat Commun
    Lu et al., 2017, MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma., Cancer Res.
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
    Togashi et al., 2015, MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor., Lung Cancer
    Olivero et al., 1999, Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family., Int. J. Cancer
    Zhu YC et al., 2018, Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing., Ann Oncol
    Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Chu LP et al., 2019, MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G Mutation., Oncologist
    Maulik et al., 2002, Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition., Cytokine Growth Factor Rev.
    Choueiri et al., 2017, Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer., J. Clin. Oncol.
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
    Schuller et al., 2015, The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models., Clin. Cancer Res.
    Spigel et al., 2013, Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer., J. Clin. Oncol.
    Shah et al., 2017, Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial., JAMA Oncol
    Catenacci et al., 2011, Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence., Cancer Discov
    Merchant et al., 2013, Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent., Proc. Natl. Acad. Sci. U.S.A.
    Cheng et al., 2015, Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma., Cancer Res.
    Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
    Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
    Busnena BA et al., 2013, Olive secoiridoids and semisynthetic bioisostere analogues for the control of metastatic breast cancer., Bioorg Med Chem
    Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett
    Paik PK et al., 2020, Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations., N Engl J Med
    Medová M et al., 2013, The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants., Mol Cancer Ther
    Choueiri et al., 2013, Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma., J. Clin. Oncol.
    Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
    Nakagawa et al., 2010, E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models., Cancer Sci.
    Minuti et al., 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer., Br. J. Cancer
    Rosen et al., 2017, A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer., Clin. Cancer Res.
    Wang et al., 2017, ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence., Clin. Cancer Res.
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med
    Hong JY et al., 2011, Growth inhibition of human lung cancer cells via down-regulation of epidermal growth factor receptor signaling by yuanhuadine, a daphnane diterpene from Daphne genkwa., J Nat Prod
    Fujita et al., 2013, The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile., Mol. Cancer Ther.
    Egile et al., 2015, The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer., Mol. Cancer Ther.
    Zhang D et al., 2013, Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors., Bioorg Med Chem
    Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science
    Rho et al., 2014, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation., Cancer Res.
    Shien et al., 2013, Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells., Cancer Res.
    Yamaoka et al., 2016, Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation., Mol. Cancer Ther.
    Smith et al., 2015, Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2., Mol. Cancer Ther.
    Piao et al., 2016, Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models., Neuro-oncology
    Kwon et al., 2015, Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment., Oncogene
    McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A
    Ninomiya K et al., 2018, MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib., Sci Rep
    Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
    Dai et al., 2012, Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation., Clin. Exp. Metastasis
    Dai et al., 2010, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro., Mol. Cancer Ther.
    Hugo et al., 2015, Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance., Cell
    Dabir et al., 2014, RET mutation and expression in small-cell lung cancer., J Thorac Oncol
    Hong DS et al., 2015, A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors., Oncotarget
    Sameni et al., 2016, Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models., Clin. Cancer Res.
    Kurzrock et al., 2011, Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer., J. Clin. Oncol.
    Goyal et al., 2017, A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma., Cancer
    Nakatani M et al., 2017, The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;., Anticancer Res
    Yakes et al., 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth., Mol. Cancer Ther.
    Moores et al., 2016, A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors., Cancer Res.
    Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem
    Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
    Liu et al., 2014, LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth., Clin. Cancer Res.
    Larsen CA et al., 2009, Tea catechins inhibit hepatocyte growth factor receptor (MET kinase) activity in human colon cancer cells: kinetic and molecular docking studies., J Med Chem
    Arena S et al., 2007, Genetic targeting of the kinase activity of the Met receptor in cancer cells., Proc Natl Acad Sci U S A
    Wittman MD et al., 2009, Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development., J Med Chem
    Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect
  • TIVANTINIB   MET

    Interaction Score: 3.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Lung, Prostate
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    CancerCommons TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • TEPOTINIB   MET

    Interaction Score: 3.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    25736998 32469185 24061647


    Sources:
    DTC CIViC TTD GuideToPharmacology ChemblInteractions

  • ONARTUZUMAB   MET

    Interaction Score: 2.89

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type esophagus adenocarcinoma
    Indication/Tumor Type gastroesophageal junction adenocarcinoma
    Response Type no benefit

    PMIDs:
    24101053 27918764 22389872 23882082


    Sources:
    CancerCommons JAX-CKB TdgClinicalTrial CIViC TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • SAVOLITINIB   MET

    Interaction Score: 2.65

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    28644771 31315834 27694386 25779944 28396313


    Sources:
    JAX-CKB CIViC TTD COSMIC GuideToPharmacology ChemblInteractions

  • EMIBETUZUMAB   MET

    Interaction Score: 2.41

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction binding constant for hMET extracellular domain measured using proprietary BIACore&reg; technology
    Specific Action of the Ligand Binding
    Endogenous Drug? False

    PMIDs:
    27803065 25231402


    Sources:
    JAX-CKB TTD GuideToPharmacology

  • CAPMATINIB   MET

    Interaction Score: 2.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Indication/Tumor Type lung large cell carcinoma
    Response Type sensitive

    PMIDs:
    28783719 27694386 25971938 28765324 15494073 32877583 28396313


    Sources:
    CancerCommons OncoKB JAX-CKB CIViC TTD DrugBank COSMIC TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • AMG-208   MET

    Interaction Score: 1.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    26155941


    Sources:
    DrugBank ChemblInteractions

  • TELISOTUZUMAB   MET

    Interaction Score: 1.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB TTD ChemblInteractions

  • TELISOTUZUMAB VEDOTIN   MET

    Interaction Score: 1.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Phase I

    PMIDs:
    27573171


    Sources:
    JAX-CKB TTD

  • SGX-523   MET

    Interaction Score: 1.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    DrugBank GuideToPharmacology ChemblInteractions

  • CRIZOTINIB   MET

    Interaction Score: 1.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    26729443 12460923 27595477 27343442 21716144 27694386 9826708 22594847 31584608 26779812 25971938 25922291 22162573 31416808 31809977 1104268 25971939 21623265 28514312 17483355 27325282 27149990 22162641 31932802 26483207 25232318 28765324 21266357 26892698 10592235 27393507 25157968 27283993 28522754 23729478 26432108 15494073 26547802 10417759 30339198 28396313 31391294 11750879


    Sources:
    ClearityFoundationBiomarkers MyCancerGenomeClinicalTrial OncoKB PharmGKB DoCM JAX-CKB TdgClinicalTrial CIViC TTD DrugBank COSMIC TALC MyCancerGenome GuideToPharmacology ChemblInteractions CGI

  • CHEMBL509101   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CHEMBL462712   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CHEMBL561660   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CHEMBL527066   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CHEMBL503090   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • EUCALYPTIN A   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • MACROCARPAL B   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • GALLOCATECHIN GALLATE   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • MACROCARPAL A   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22934600


    Sources:
    DTC

  • EMD-1204831   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TTD ChemblInteractions

  • (-)-OLEOCANTHAL   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23403296


    Sources:
    DTC

  • PF-04217903   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    DTC TTD COSMIC TALC MyCancerGenome ChemblInteractions

  • JNJ-38877605   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TTD ChemblInteractions

  • SAR-125844   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Indication/Tumor Type lung cancer

    PMIDs:
    25504634


    Sources:
    JAX-CKB TTD ChemblInteractions

  • TYROSOL SINAPATE   MET

    Interaction Score: 0.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23403296


    Sources:
    DTC

  • GOLVATINIB   MET

    Interaction Score: 0.8

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Details of the Assay for Interaction Measured as inhibition of c-MET phosphorylation in MKN45 cells

    PMIDs:
    19832844


    Sources:
    JAX-CKB TTD GuideToPharmacology ChemblInteractions

  • OSIMERTINIB   MET

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Response Type resistant
    Evidence Type Actionable

    PMIDs:
    27694386 29386539 27393507 27252416


    Sources:
    OncoKB JAX-CKB CIViC CGI

  • CHEMBL261641   MET

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17595299 23403296


    Sources:
    DTC

  • JNJ-61186372   MET

    Interaction Score: 0.72

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    27216193


    Sources:
    JAX-CKB GuideToPharmacology

  • TAS-115   MET

    Interaction Score: 0.72

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Indication/Tumor Type stomach cancer

    PMIDs:
    24140932


    Sources:
    JAX-CKB ChemblInteractions

  • PHA-665752   MET

    Interaction Score: 0.67

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Gefitinib + PHA-665752
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    18077425 24165158 21266357 23542356


    Sources:
    DTC JAX-CKB GuideToPharmacology

  • BMS-777607   MET

    Interaction Score: 0.64

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    22286523 20515943 28396313


    Sources:
    JAX-CKB TTD MyCancerGenome GuideToPharmacology ChemblInteractions

  • CABOZANTINIB   MET

    Interaction Score: 0.6

    Interaction Types & Directionality:
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    27694386 26432786 21606412 25971939 28192597 29061793 21926191 28396313


    Sources:
    ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial OncoKB JAX-CKB TdgClinicalTrial CIViC TTD DrugBank TALC MyCancerGenome GuideToPharmacology CGI

  • GLESATINIB   MET

    Interaction Score: 0.54

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Reported Cancer Type Lung
    Trial Name MGCD265

    PMIDs:
    27694386 28765324 15494073


    Sources:
    CancerCommons JAX-CKB TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology

  • NAQUOTINIB   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29386539


    Sources:
    CIViC

  • MK-8033   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    TTD ChemblInteractions

  • EMI-137   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Details of the Assay for Interaction <i>In vitro</i> fluorescence polarization assay.
    Specific Action of the Ligand Binding
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • COMETRIQ   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma

    PMIDs:
    None found


    Sources:
    CancerCommons

  • APRATOXIN F   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BMS-698769   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • AMG-337   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    GuideToPharmacology ChemblInteractions

  • AMUVATINIB   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes
    Trial Name MP-470

    PMIDs:
    24326130


    Sources:
    JAX-CKB TdgClinicalTrial DrugBank TALC MyCancerGenome ChemblInteractions

  • FICLATUZUMAB   MET

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type multiple myeloma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    24901237


    Sources:
    JAX-CKB

  • ALTIRATINIB   MET

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Approval Status Preclinical

    PMIDs:
    26285778 26965451 24362531


    Sources:
    JAX-CKB TTD GuideToPharmacology ChemblInteractions

  • K-252A   MET

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235 17139284 17016423


    Sources:
    DrugBank

  • FORETINIB   MET

    Interaction Score: 0.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Preclinical
    combination therapy Foretinib + Rucaparib
    Evidence Type Actionable

    PMIDs:
    23213094 26779812


    Sources:
    CancerCommons JAX-CKB TdgClinicalTrial CIViC TTD TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • EPICATECHIN GALLATE   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • BPI-9016   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ALVESPIMYCIN   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • LY-3164530   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CMX-2043   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • CABOZANTINIB S-MALATE   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BMS-794833   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BMS-817378   MET

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • YUANHUADINE   MET

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21916433


    Sources:
    DTC

  • ENSARTINIB   MET

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Result from DiscoveRx KINOMEscan&reg; selectivity screen.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • ROCILETINIB   MET

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration MET:amp
    Drug family [EGFR inhibitor 3rd gen]

    PMIDs:
    None found


    Sources:
    CGI

  • ARRY-300   MET

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MK-2461   MET

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    TTD MyCancerGenome GuideToPharmacology ChemblInteractions

  • MERESTINIB   MET

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Inhibition of <i>in vitro</i> biochemical activity by EMD Millipore assay.
    Direct Interaction? False
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology ChemblInteractions

  • GANETESPIB   MET

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • AFATINIB   MET

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    27694386


    Sources:
    JAX-CKB

  • VELIPARIB   MET

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • MGCD-265   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Hepatocyte growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TRASTUZUMAB   MET

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

    PMIDs:
    22850551 26432108


    Sources:
    JAX-CKB CGI

  • BMS-754807   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19778024


    Sources:
    DTC

  • SITRAVATINIB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction In a biochemical enzyme activity assay.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    TTD GuideToPharmacology

  • LAPATINIB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Drug family ERBB2 inhibitor
    Alteration MET:amp;ERBB2:amp
    combination therapy Crizotinib + Lapatinib

    PMIDs:
    27595477 26432108


    Sources:
    JAX-CKB CGI

  • CHEMBL399530   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PANITUMUMAB   MET

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy JNJ 38877605 + Panitumumab
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23729478


    Sources:
    JAX-CKB CGI

  • VEMURAFENIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration MET:amp;BRAF:V600E
    Drug family BRAF inhibitor;EGFR mAb inhibitor
    combination therapy Vemurafenib;Panitumumab

    PMIDs:
    27325282 26359985


    Sources:
    CIViC CGI

  • GEFITINIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    combination therapy Gefitinib + NPS-1034
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23993328 17463250 24165158 23542356 27612490


    Sources:
    DTC OncoKB JAX-CKB CIViC

  • ALECTINIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • CRENOLANIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • SELUMETINIB   MET

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + BEZ235
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    25952648 24939055


    Sources:
    JAX-CKB CIViC

  • ERLOTINIB   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Onartuzumab + Erlotinib
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type conflicting

    PMIDs:
    27694386 27803065 24101053


    Sources:
    DTC OncoKB JAX-CKB

  • CEP-11981   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22148921


    Sources:
    DTC

  • BRIGATINIB   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DrugBank

  • PILARALISIB   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25637314


    Sources:
    JAX-CKB

  • BEVACIZUMAB   MET

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Altiratinib + Bevacizumab
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    26965451 26432108 25363205


    Sources:
    JAX-CKB

  • TRAMETINIB   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy INC280 + Trametinib
    Indication/Tumor Type collecting duct carcinoma
    Response Type sensitive

    PMIDs:
    28783719 25952648


    Sources:
    JAX-CKB CIViC

  • TANESPIMYCIN   MET

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Details of the Assay for Interaction Measuring downstream uPA-plasmin inhibition.
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • LEUCOVORIN   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • EPIGALOCATECHIN GALLATE   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19839593


    Sources:
    DTC

  • OLAPARIB   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • DACTOLISIB   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24939055


    Sources:
    DTC JAX-CKB

  • PONATINIB   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung small cell carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25122427


    Sources:
    JAX-CKB

  • CETUXIMAB   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy Cetuximab + JNJ 38877605
    Approval Status Preclinical - Cell culture

    PMIDs:
    23729478


    Sources:
    JAX-CKB CIViC

  • RUCAPARIB   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    combination therapy Foretinib + Rucaparib
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26779812


    Sources:
    JAX-CKB

  • CHEMBL202721   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CAPECITABINE   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    Evidence Type Actionable
    Approval Status Clinical Study

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • OXALIPLATIN   MET

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • CHEMBL546797   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PACLITAXEL   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type gastric adenocarcinoma
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    Evidence Type Actionable

    PMIDs:
    28514312 26432108


    Sources:
    JAX-CKB

  • IMATINIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • CHEMBL541400   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CARBOPLATIN   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • DASATINIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    26483207


    Sources:
    JAX-CKB

  • CHEMBL1997335   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SNS-314   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SORAFENIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type gastrointestinal stromal tumor
    Response Type sensitive

    PMIDs:
    25363205


    Sources:
    JAX-CKB

  • OSI-632   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PAZOPANIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PALBOCICLIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • JNJ-7706621   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PD-0166285   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUOROURACIL   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • ENTRECTINIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • LINIFANIB   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • R-406   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SP-600125   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CYC-116   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TAE-684   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PF-00562271   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ILORASERTIB   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FOSTAMATINIB   MET

    Interaction Score: 0.0

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    26516587


    Sources:
    DrugBank

  • Ensembl: ENSG00000105976

    • Version: 101_38

    Alternate Names:
    MET Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P08581

    • Version: January-2014

    Alternate Names:
    MET Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass EC:2.7.10.1

    Publications:

  • CancerCommons: MET

    • Version: 25-July-2013

    Alternate Names:
    4233 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name MET
    CancerCommons Reported Gene Name MET, VEGFRs, Axl, Tie2, Ron

    Publications:

  • BaderLabGenes: MET

    • Version: February-2014

    Alternate Names:
    4233 Entrez Gene ID

    Gene Info:
    Initial Gene Query MET
    Counted Citations from 1950-2000 4560

    Gene Categories:
    KINASE

    Publications:

  • HopkinsGroom: P08581

    • Version: 11-September-2012

    Alternate Names:
    MET_HUMAN Uniprot Id
    4233 Entrez Gene Id
    P08581 Uniprot Accession

    Gene Info:
    Human Readable Name KINASE
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000105976

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000105976 Ensembl Gene Id
    MET Display Id
    HEPATOCYTE GROWTH FACTOR RECEPTOR PRECURSOR (EC 2.7.1.112) (MET PROTO- ONCOGENE TYROSINE KINASE) (C-MET) (HGF RECEPTOR) (HGF-SF RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08581] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • GuideToPharmacology: 4233

    • Version: 29-September-2020

    Alternate Names:
    7029 HUGO Gene ID
    7029 HUGO Gene Symbol
    MET proto-oncogene, receptor tyrosine kinase HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Type X RTKs: HGF (hepatocyte growth factor) receptor family
    GuideToPharmacology Gene Category ID 325

    Publications:

  • JAX-CKB: MET

    • Version: 27-September-2017

    Alternate Names:
    4233 CKB Entrez Id
    MET CKB Gene Synonym
    AUTS9 CKB Gene Synonym

    Gene Info:

    Publications:
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Engelman et al., 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling., Science

  • PharmGKB: MET

    • Version: 18-August-2020

    Alternate Names:
    PA30763 PharmGKB ID

    Gene Info:

    Publications:
    Ou SH, 2011, Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond., Drug Des Devel Ther

  • CIViC: MET

    • Version: 14-September-2020

    Alternate Names:
    4233 Entrez Gene ID
    52 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Bardelli et al., 2013, Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer., Cancer Discov
    Lee J et al., 2019, Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial., Cancer Discov
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov

  • DrugBank: BE0000915

    • Version: 5.1.7

    Alternate Names:
    MET DrugBank Gene Name
    P08581 UniProt Accession
    4233 Entrez Gene Id

    Gene Info:

    Publications:
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Hong DS et al., 2015, A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors., Oncotarget
    Forde et al., 2012, Crizotinib in the treatment of non-small-cell lung cancer., Expert Opin Pharmacother

  • CGI: MET

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Minuti et al., 2012, Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer., Br. J. Cancer
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

  • DoCM: MET

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Lorenzato et al., 2002, Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion., Cancer Res.
    Bardelli et al., 1998, Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth., Proc. Natl. Acad. Sci. U.S.A.
    Dalinka et al., 1975, The radiology of osseous and articular infection., CRC Crit Rev Clin Radiol Nucl Med

  • DTC: MET

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    McDermott U et al., 2007, Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling., Proc Natl Acad Sci U S A
    Yang SP et al., 2012, Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity., J Med Chem
    Dorsch D et al., 2015, Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors., Bioorg Med Chem Lett

  • TALC: MET

    • Version: 12-May-2016

    Alternate Names:
    MET Gene Symbol

    Gene Info:

    Publications:

  • TALC: HGFR

    • Version: 12-May-2016

    Alternate Names:
    HGFR Gene Symbol

    Gene Info:

    Publications:

  • MyCancerGenome: MET

    • Version: 20-Jun-2017

    Alternate Names:
    4233 Entrez Gene Id
    MET MyCancerGenome Gene Symbol
    MET MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000105976

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000105976 Gene Symbol
    MET Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: C-MET

    • Version: 12-May-2016

    Alternate Names:
    C-MET Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: MET

    • Version: chembl_23

    Alternate Names:
    MET GENE_SYMBOL
    Hepatocyte growth factor receptor UNIPROT
    HGF/SF receptor UNIPROT

    Gene Info:

    Publications:

  • OncoKB: MET

    • Version: 23-July-2020

    Alternate Names:
    4233 OncoKB Entrez Id
    RCCP2 OncoKB Gene Synonym
    HGFR OncoKB Gene Synonym

    Gene Info:

    Publications:

  • Pharos: MET

    • Version: 03-September-2020

    Alternate Names:
    Hepatocyte growth factor receptor Gene Name
    P08581 UniProt ID

    Gene Info:

    Gene Categories:
    KINASE

    Publications:

  • Tempus: MET

    • Version: 11-November-2018

    Alternate Names:
    MET Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: MET

    • Version: 27-Jun-2013

    Alternate Names:
    4233 Gene ID
    AUTS9 dGene Synonym
    HGFR dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, TYROSINE KINASE

    Publications:

  • TTD: Proto-oncogene c-Met

    • Version: 2020.06.01

    Alternate Names:
    MET TTD Gene Abbreviation
    T40474 TTD Target ID

    Gene Info:

    Publications:

  • MyCancerGenomeClinicalTrial: MET

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: MET

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • ClearityFoundationBiomarkers: MET

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: MET

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: C-MET

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: MET

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: MET

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • GO: MET

    • Version: 05-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CELL SURFACE, TYROSINE KINASE

    Publications:

  • Oncomine: MET

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • COSMIC: MET

    • Version: 4-Sep-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21